Search

Your search keyword '"Ebert, Matthias"' showing total 1,686 results

Search Constraints

Start Over You searched for: Author "Ebert, Matthias" Remove constraint Author: "Ebert, Matthias"
1,686 results on '"Ebert, Matthias"'

Search Results

3. Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients

10. The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effects

11. Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study

13. Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B

14. Engineering the gut microbiome

16. Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction

24. Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes

25. Tolerance of repeated toxic injuries of murine livers is associated with steatosis and inflammation

28. Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial

30. Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 knockout mice with a humanized bile acid composition.

31. Associations Between Brain Morphology, Inflammatory Markers, and Symptoms of Fatigue, Depression, or Anxiety in Active and Remitted Crohn's Disease.

33. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

34. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

35. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

36. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

37. Situation klinischer Studien in Deutschland – ein interdisziplinäres Positionspapier

38. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

39. The drug-induced phenotypic landscape of colorectal cancer organoids

41. Functional antagonism between CagA and DLC1 in gastric cancer

42. An organoid platform reveals MEK-PARP co-targeting to enhance radiation response in rectal cancer

44. THU-164-YI Evaluation of four chatbots in autoimmune liver disease: a comparative analysis

46. Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study

Catalog

Books, media, physical & digital resources